首页 › 头颈鳞状细胞癌 › 马里兰州 › Baltimore
Baltimore MD 头颈鳞状细胞癌临床试验
15项针对 头颈鳞状细胞癌的研究正在 Baltimore及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
招募中2/3 期
- Site #0112, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #14, Baltimore
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- University of Maryland/Greenebaum Cancer Center, Baltimore
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
招募中3 期
- University of Maryland Greenebaum Cancer Center, Baltimore
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
招募中1/2 期
- University of Maryland School of Medicine, Baltimore
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
招募中2 期
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie · 距离 9 英里
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Greater Baltimore Medical Center, Baltimore
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
招募中2 期
- Research Site, Baltimore
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
招募中观察性研究
- University of Maryland, Baltimore
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
招募中2 期
- Greater Baltimore Medical Center, Baltimore
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- Johns Hopkins Hospital /ID# 254056, Baltimore
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
招募中3 期
- University of Maryland, Baltimore
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
招募中2 期
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · 距离 9 英里
- 以及另外 1 项
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
其他城市的 头颈鳞状细胞癌试验
- Houston, TX47 项研究
- Los Angeles, CA42 项研究
- Boston, MA40 项研究
- New York City, NY39 项研究
- Nashville, TN39 项研究
- St. Louis, MO28 项研究
- Arlington, VA26 项研究
- Chicago, IL26 项研究
- Philadelphia, PA26 项研究
- Atlanta, GA24 项研究
- San Antonio, TX22 项研究
- New Haven, CT22 项研究
Baltimore的其他研究
- 非小细胞肺癌60 项研究
- 乳腺癌47 项研究
- 前列腺癌43 项研究
- 肺癌40 项研究
- 癌症（所有类型）37 项研究
- 胰腺癌31 项研究
- 结直肠癌31 项研究
- 转移性癌症28 项研究
- 肥胖症26 项研究
- 膀胱癌24 项研究
- 心力衰竭24 项研究
- 卵巢癌22 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。